Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biogen Idec takes over Neurimmune subsidiary
Biogen Idec will make an initial payment of $32.5m and up to $395m in contingent payments. Biogen Idec and Neurimmune said that the acquisition builds on a 2007
Biogen Idec will make an initial payment of $32.5m and up to $395m in contingent payments. Biogen Idec and Neurimmune said that the acquisition builds on a 2007
Colistin is an antibiotic used to treat the principal bacterial infections in cystic fibrosis (CF) patients, and Colobreathe is a novel dry powder inhaler containing Colistin developed by
Arresto develops medicines that target enzymes involved in the synthesis of the extracellular matrix, which appear to play a role in the etiology of a variety of fibrotic
VistaGen’s initial AV-101 Phase 1 clinical trial was a randomized, double-blind, placebo-controlled study designed to evaluate the safety and pharmacokinetics of single doses of AV-101 in two cohorts
For the study, David Myszka, founder of Biosensor Tools and director of the Center for Biomolecular Interaction Analysis at the University of Utah, used surface plasmon resonance (SPR)
In the first two cohorts of healthy volunteers, the safety, tolerability, pharmacokinetics and optimal formulation of the candidate compound will be evaluated during a placebo controlled dose escalation.
Under the agreement, Oncolys may receive up to $286m as well as upfront, development, regulatory and sales milestone payments. In addition, Oncolys is eligible to receive tiered royalties
Megapharm is EpiCept’s partner in Israel and upon Ministry of Health approval of labeling and other technical matters the company is expected to launch Ceplene in the first
The technology creates transient bonds between larger molecules such as proteins and peptides, including insulin, and a carrier.Ascendis Pharma claims that the TransCon Linker technology has shown promising
Haojishi is an anti-inflammatory analgesic poultice that contains glycol salicylate and menthol as two of its main ingredients. Available in China as a prescription medication, the product comes